Dermatofibrosarcoma protuberans: Treatment options

Current Opinion in Orthopaedics

Volumn 15, Issue 6, 2004, Pages 447-451

  Willers, Henning ^a   DeLaney, Thomas F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Dermatofibrosarcoma protuberans; Imatinib; Molecular targeting; Radiation; Resection margins; Treatment

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; IMATINIB;

CANCER CHEMOTHERAPY; CHEMOSURGERY; DERMATOFIBROSARCOMA PROTUBERANS; HUMAN; PATHOGENESIS; PRIMARY HEALTH CARE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 8544242739     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bco.0000145094.73384.0c     Document Type: Review

References (22)

1. Gloster HM Jr: Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996, 35:355-374.
2. Ratner D, Thomas CO, Johnson TM, et al.: Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997, 37:600-613.
3. Lindner NJ, Scarborough MT, Powell GJ, et al.: Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. Eur J Surg Oncol 1999, 25:392-397.
4. Mentzel T, Beham A, Katenkamp D, et al.: Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998, 22:576-587.
5. Kransdorf MJ: Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. Am J Roentgenol 1995, 164:129-134.
6. Ballo MT, Zagars GK, Pisters P, et al.: The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 1998, 40:823-827.
7. Khatri VP, Galante JM, Bold RJ, et al.: Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol 2003, 10:1118-1122.
8. DuBay D, Cimmino V, Lowe L, et al.: Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004, 100:1008-1016. This institutional experience from the University of Michigan reports on a relatively large series of 62 patients with DFSP. This paper suggests that careful pathologic analysis of margin status after wide excision to achieve negative margins, as well as a multidisciplinary treatment approach, contributes to improved local control.
9. Chang CK, Jacobs IA, Salti GI: Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004, 30:341-345.
10. Wacker J, Khan-Durani B, Hartschuh W: Modified Mohs micrographic surgery in the therapy of dermatofibrosarcoma protuberans: analysis of 22 patients. Ann Surg Oncol 2004, 11:438-444. This institutional experience from the University of Heidelberg, Germany, reports on the authors' experience with Mohs surgery for 22 patients with DFSP. The authors stress the importance of insuring the presence of true negative margins by using paraffin sectioning as part of the surgical procedure.
11. Tom WD, Hybarger CP, Rasgon BM: Dermatofibrosarcoma protuberans of the head and neck: treatment with Mohs surgery using inverted horizontal paraffin sections. Laryngoscope 2003, 113:1289-1293.
12. Linn SC, West RB, Pollack JR, et al.: Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 2003, 163:2383-2395. This multicenter effort led by Stanford University identified a distinctive gene expression profile for DFSP, which has the potential to yield additional markers and possible new molecular target genes in the future.
13. Suit H, Spiro I, Mankin HJ, et al.: Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol 1996, 14:2365-2369.
14. McArthur G: Molecularly targeted treatment for Dermatofibrosarcoma protuberans. Semin Oncol 2004, 31:30-36. Excellent recent review of the molecular targeting of DFSP by imatinib and summary of the clinical experience to date.
15. Sirvent N, Maire G, Pedeutour F: Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003, 37:1-19. Detailed review of the molecular pathogenesis of DFSP.
16. Pietras K, Sjoblom T, Rubin K, et al.: PDGF receptors as cancer drug targets. Cancer Cell 2003, 3:439-443.
17. Nielsen TO, West RB, Linn SC, et al.: Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002, 359:1301-1307.
18. Nemunaitis J, Holmlund JT, Kraynak M, et al.: Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 1999, 17:3586-3595.
19. Takahira T, Oda Y, Tamiya S, et al.: Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans. Hum Pathol 2004, 35:240-245.
20. McArthur GA, Demetri GD, Heinrich M, et al.: Molecular and clinical analysis of response to imatinib for locally advanced dermatofibrosarcoma protuberans. Proc Am Soc Clin Oncol 2003, 22:195.
21. Corless C, Heinrich MC, Dimitrijevic S, et al.: Correlation of imatinib response with activation of KIT and PDGF receptors in a variety of cancers: results of the CSTIB2225 trial. Proc Am Soc Clin Oncol 2003, 22:195.
22. Macapinlac M, Elrafei T, Cunningham I, et al.: Dermatofibrosarcoma protuberans: neoadjuvant therapy with imatinib mesylate and use of plasma PDGF-B levels to monitor clinical response. Proc Am Soc Clin Oncol 2004.(in press)